BioMarin Pharma (BMRN) Posts Q4 Loss of $0.03/Share
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $63.37 -1.08%
Revenue Growth %: +31.4%
Financial Fact:
Selling, general and administrative: 118.76M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Revenue Growth %: +31.4%
Financial Fact:
Selling, general and administrative: 118.76M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q4 GAAP EPS of ($0.03), which may not compare to the analyst estimate of ($0.24). Revenue for the quarter came in at $353.2 million versus the consensus estimate of $377.35 million.
GUIDANCE:
BioMarin Pharma sees FY2019 revenue of $1.68-1.75 billion, versus the consensus of $1.73 billion.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- KB Home (KBH) Tops Q3 EPS by 16c
- MillerKnoll, Inc. (MLKN) Tops Q1 EPS by 18c ; Offers Guidance
- Goldman: 'Our key conclusion is that AI is likely to be credit-positive for banks', 'Rearming Our Overweight Stance on Banks'
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
